Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB

Catalyst Biosciences (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced top-line data from its Phase 1/2 study of subcutaneous prophylactic candidate CB 2679d/ISU304 being developed for the treatment of hemophilia B in an oral presentation at the 11^th Annual Congress of The European Association for Haemophilia and Allied Disorders (EAHAD) in Madrid.

As quoted in the press release:

“These exciting results demonstrate for the first time the feasibility of a subcutaneous FIX injection to provide meaningful protection from bleeding, even after only six doses,” said Dr. John Pasi, professor of haemostasis and thrombosis at Barts and The London School of Medicine and Dentistry. “As a result, this treatment option has the potential to normalize coagulation activity and dramatically improve the quality of life of individuals affected by hemophilia B.”

Click here to read the full press release.